Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

Abstract DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Katharina Bolsewig, Eline A. J. Willemse, Pascual Sánchez-Juan, Alberto Rábano, Minerva Martínez, James D. Doecke, Giovanni Bellomo, Lisa Vermunt, Daniel Alcolea, Steffen Halbgebauer, Sjors in ‘t Veld, Niklas Mattsson-Carlgren, Katerina Veverova, Christopher J. Fowler, Lynn Boonkamp, Marleen Koel-Simmelink, Zulaiga Hussainali, Daimy N. Ruiters, Lorenzo Gaetani, Andrea Toja, Juan Fortea, Yolande Pijnenburg, Afina W. Lemstra, Wiesje M. van der Flier, Jakub Hort, Markus Otto, Oskar Hansson, Lucilla Parnetti, Colin L. Masters, Alberto Lleó, Charlotte E. Teunissen, Marta Del Campo Milán
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56293-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-56293-z

Similar Items